Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

DRAXIS Establishes Share Buyback Program.


Business Editors

MISSISSAUGA, Ontario--(BUSINESS WIRE)--April 16, 2003

DRAXIS Health Inc. (Nasdaq: DRAX)(TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension
: DAX) has received approval from The Toronto Stock Exchange Toronto Stock Exchange (TSE)

Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options.
 to make a Normal Course Issuer Bid to repurchase re·pur·chase  
tr.v. re·pur·chased, re·pur·chas·ing, re·pur·chas·es
To buy (something) again.

n.
The act of buying something that one previously sold or owned.

Noun 1.
 for cancellation up to 1,854,934 common shares, the maximum allowable number, representing 5% of the 37,098,690 common shares issued and outstanding.

Under the program, DRAXIS is able to begin purchases of its shares through the facilities of the Toronto Stock Exchange beginning April 21, 2003. The bid will end no later than April 20, 2004 or earlier if the Company purchases the maximum allowable number of shares.

The Board of Directors of DRAXIS believes the underlying value of the Company is not reflected in the current market price of its common shares and have thus concluded that the repurchase of common shares presently constitutes an appropriate use of financial resources and would be in the best interest of shareholders.

DRAXIS has not purchased any of its own shares in the past twelve months.

About DRAXIS Health Inc.

DRAXIS Health Inc. is a specialty pharmaceutical company focused on the development, production, marketing and distribution of radiopharmaceuticals (DRAXIMAGE) and the provision of pharmaceutical contract manufacturing services, specializing in liquid and freeze-dried injectables and other sterile sterile /ster·ile/ (ster´il)
1. unable to produce offspring.

2. aseptic.


ster·ile
adj.
1. Not producing or incapable of producing offspring.

2.
 products (DRAXIS Pharma).

Except for historical information, this news release contains certain forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995 as amended a·mend  
v. a·mend·ed, a·mend·ing, a·mends

v.tr.
1. To change for the better; improve: amended the earlier proposal so as to make it more comprehensive.

2.
, which involve risk and uncertainties that may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, timely regulatory approval of the Company's products, the ability to obtain and enforce effective patents, the establishment and maintenance of new corporate alliances, compliance with appropriate governmental regulations, and other risks detailed from time-to-time in the Company's filings with the US Securities and Exchange Commission and Canadian securities authorities. The Company does not undertake to update such forward-looking statements to reflect new information, later events or developments.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Apr 16, 2003
Words:330
Previous Article:Alcon Announces First Quarter 2003 Earnings Release.
Next Article:Crossroads Teams With Quantum To Provide Two Gigabit Fibre Channel Connectivity.
Topics:



Related Articles
DRAXIS files preliminary prospectus.
SGF to Invest in DRAXIS' Manufacturing Subsidiary, DRAXIS Pharma.
DRAXIS Health Reports Fourth Quarter and Full Year 1999 Results Full Year Revenues Increase by 31% to $43 Million.
DRAXIS Health Reports First Quarter Results.
DRAXIS Signs Five-Year Manufacturing and Supply Contract With Virco Pharmaceuticals.
Share Repurchase: To Buy or Not to Buy.
DRAXIS Accepted by FDA to Manufacture Solid Dosage Form Products; Approval Opens Doors to Additional Markets in the U.S.
DRAXIS Manufacturing Site Approved By UK Regulator.
DRAXIS Health Reports First Quarter Results.
DRAXIS Realigns Executive Management Team.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles